We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down
Read MoreHide Full Article
Shares of Bausch Health Companies Inc. (BHC - Free Report) are down 12.9% in the week so far. The company along with its wholly-owned subsidiary, Salix Pharmaceuticals, and Salix's licensor Alfasigma announced that they have filed a lawsuit against Sandoz Inc., the generics division of Novartis (NVS - Free Report) .
The lawsuit alleges infringement of 14 Xifaxan patents by Sandoz's filing of an Abbreviated New Drug Application (ANDA) for Xifaxan 550 mg.
Consequently, the stock declined. Per Bausch, Xifaxan is protected by 22 patents, covering the composition of matter and the use of Xifaxan listed in the U.S. Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book.
The drug is approved for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. Bausch’s Salix business continues to drive growth and contribute to the top line. We note that Xifaxan is one of the key drugs for the company and increased sales of the drug are boosting sales. Revenues from the drug increased 16% in the first half of 2019 and contributed significantly to Salix’s revenues of $954 million.
Bausch’s stock has gained 2.3% in the year so far against a decline of 10% for the industry.
We remind investors that Bausch was also involved in a patent litigation with Actavis, now a part of Teva Pharmaceuticals (TEVA - Free Report) , in 2016. The company agreed to resolve the outstanding intellectual property litigation with Actavis regarding Xifaxan 550 mg tablets in September 2018. Per the agreement, the Salix Parties granted Actavis a non-exclusive license to the former’s intellectual property relating to Xifaxan 550 mg tablets in the United States effective Jan 1, 2028.
Bausch has currently narrowed its focus on seven products — Vyzulta, Siliq, Bryhali, Lumify, Duobrii, Relistor and SiHy Daily. These products have now been launched and hence the company’s performance in the second half of the year is expected to be strong. After a tumultuous period, Bausch started a rebuilding process. Even though there is still a long way to go, the company’s efforts to sell non-core assets and pay down huge levels of debt are commendable.
Earnings estimates for Incyte have gone up 12 cents to $2.56 for 2019 in the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down
Shares of Bausch Health Companies Inc. (BHC - Free Report) are down 12.9% in the week so far. The company along with its wholly-owned subsidiary, Salix Pharmaceuticals, and Salix's licensor Alfasigma announced that they have filed a lawsuit against Sandoz Inc., the generics division of Novartis (NVS - Free Report) .
The lawsuit alleges infringement of 14 Xifaxan patents by Sandoz's filing of an Abbreviated New Drug Application (ANDA) for Xifaxan 550 mg.
Consequently, the stock declined. Per Bausch, Xifaxan is protected by 22 patents, covering the composition of matter and the use of Xifaxan listed in the U.S. Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book.
The drug is approved for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. Bausch’s Salix business continues to drive growth and contribute to the top line. We note that Xifaxan is one of the key drugs for the company and increased sales of the drug are boosting sales. Revenues from the drug increased 16% in the first half of 2019 and contributed significantly to Salix’s revenues of $954 million.
Bausch’s stock has gained 2.3% in the year so far against a decline of 10% for the industry.
We remind investors that Bausch was also involved in a patent litigation with Actavis, now a part of Teva Pharmaceuticals (TEVA - Free Report) , in 2016. The company agreed to resolve the outstanding intellectual property litigation with Actavis regarding Xifaxan 550 mg tablets in September 2018. Per the agreement, the Salix Parties granted Actavis a non-exclusive license to the former’s intellectual property relating to Xifaxan 550 mg tablets in the United States effective Jan 1, 2028.
Bausch has currently narrowed its focus on seven products — Vyzulta, Siliq, Bryhali, Lumify, Duobrii, Relistor and SiHy Daily. These products have now been launched and hence the company’s performance in the second half of the year is expected to be strong. After a tumultuous period, Bausch started a rebuilding process. Even though there is still a long way to go, the company’s efforts to sell non-core assets and pay down huge levels of debt are commendable.
Zacks Rank & Another Stock to Consider
Bausch currently carries a Zacks Rank #2 (Buy). Another top-ranked stock in the healthcare sector is Incyte Corp. (INCY - Free Report) with a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings estimates for Incyte have gone up 12 cents to $2.56 for 2019 in the past 60 days.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>